Structural properties of solid lipid based colloidal drug delivery systems

For about 20 years nanoparticles based on solid lipids have been under investigation as drug carrier systems. They can be prepared from a broad variety of lipid matrix materials including glycerides, fatty acids and waxes and are stabilized by physiologically compatible surfactants. Although the matrix lipids principally retain their material properties when dispersed into the colloidal state there are various peculiarities that have to be observed when dealing with such systems. In particular, the crystallization behavior and the polymorphic transitions are altered in the nanoparticulate systems. These properties as well as the particle shape and structure may be affected by the type of surfactants used for stabilization. Also incorporated drugs can modify the structural characteristics of the nanoparticles. Interactions between the individual particles may lead to alterations of the macroscopic behavior of the dispersions, especially of their rheological properties. Such structural parameters can influence the drug carrier properties of the dispersions.     

Lipid carrier systems for targeted drug and gene delivery

For effective chemotherapy, it is necessary to deliver therapeutic agents selectively to their target sites, since most drugs are associated with both beneficial effects and side effects. The use of lipid dispersion carrier systems, such as lipid emulsions and liposomes, as carriers of lipophilic drugs has attracted particular interest. A drug delivery system can be defined as a methodology for manipulating drug distribution in the body. Since drug distribution depends on the carrier, administration route, particle size of the carrier, lipid composition of the carrier, electric charge of the carrier and ligand density of the targeting carrier, these factors must be optimized. Recently, the lipid carrier system has also been applied to gene delivery systems for gene therapy. However, in both drug and gene medicine cases, a lack of cell-selectivity limits the wide application of this kind of drug and/or gene therapy. Therefore, lipid carrier systems for targeted drug and gene delivery must be developed for the rational therapy. In this review, we shall focus on the progress of research into lipid carrier systems for drug and gene delivery following systemic or local injection.     

Synthesis of PHB-based carrier for drug delivery systems with pH-controlled release

Synthetic route to prepare model PHB-amine conjugate containing hydrolysable imine bond is reported. Short-chain PHB crotonate is converted into PHB glyoxylate via clean and efficient ozonolysis followed by reductive decomposition of peroxidic products with dimethylsulfide. Aldehyde-functionalized PHB is obtained quantitatively without polymer backbone degradation while PHB-amine conjugate is synthesized with very high yield. Release properties of such-prepared conjugate is confirmed in hydrolysis experiment revealing pH-dependent kinetics of amine release. Simplicity of the protocol in conjunction with unique properties of PHB carrier are believed to be powerful tool for development of novel drug conjugates.     

Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel

The aim of this study was to design docetaxel-loaded nanostructured lipid carriers (DTX-NLC) to reduce toxicity and improve therapeutic efficacy. Docetaxel-loaded nanostructured lipid carriers (DTX-NLC) were prepared by the modified film ultrasonication–dispersion method. The DTX-NLC were characterized by particle size distribution, zeta potential and entrapment efficiency. In vitro cytotoxicity of DTX-NLC was evaluated by MTT assay against three human cancer cell lines and one murine malignant melanoma (B16). AnnexinV-FITC kit was used to measure the percentage of apoptosis induced by Duopafei^® or DTX-NLC. In vivo anti-tumor efficacy was evaluated in Kunming mice bearing murine malignant melanoma (B16). Compared with Duopafei^®, DTX-NLC revealed more cytotoxicity against A549 cells by inducing more apoptosis and more G2/M arrest. The inhibition rates of Duopafei^®, DTX-NLC (10 mg/kg) and DTX-NLC (20 mg/kg) were 42.74%, 62.69% and 90.36%, respectively, indicating that DTX-NLC could more effectively inhibit tumor growth. The results of the body weight variations of mice also showed that compared with Duopafei^®, DTX-NLC had lower toxicity during the therapeutic procedure. These results suggest that DTX-NLC may be a promising drug delivery system for cancer therapy. To our knowledge, this was the first report about DTX-NLC for murine malignant melanoma treatment.     

Stimuli sensitive polymers for drug delivery systems

Temperature sensitive and electric field sensitive hydrogels were prepared for use in modulated drug release systems. Crosslinked poly(N-isopropyl-acrylamide) and its networks, modified with hydrophobic components by copolymerization or by interpenetrating polymer networks (IPNs) formation, were utilized as temperature sensitive hydrogels. Indomethacin (a model solute)-release from polymer matrix and permeation through polymer membrane demonstrated “on-off” regulation with temperature fluctuation. This was the result of polymer surface properties rather than bulk swelling, as temperature was changed past the swelling transition temperature range of the polymer. The on-off regulation in an electric field was also obtained with a positively charged solute (Edrophonium chloride) release in distilled-deionized water from a matrix of crosslinked poly(2-acrylamido-2-methylpropanesulfonic acid-co-butyl methacrylate). This was attributed to the ion exchange between Edrophonium ion and protons produced at the anode. The swelling changes produced by local pH or ionic strength changes affected non-charged solute release.     

Interaction between erythrocytes and free phospholipids as an emulsifying agent in fat emulsions or drug carrier emulsions for intravenous injections

Hemolysis caused by the interaction between rabbit erythrocytes and oil-in-water emulsions (e.g., fat emulsions or drug carrier emulsions for intravenous injections) prepared with various oil concentrations was investigated. In emulsions prepared with oil concentrations in the range of 2.5-12.5%, the percentage of both hemolysis and free purified egg yolk lecithins (PEL) in the water phase of the emulsions decreased with the increased oil concentration and became constant above 12.5% oil concentration. The change in free PEL percentage in the water phase of the emulsions prepared with various oil concentrations showed the same relationship as that of the percentage hemolysis caused by the interaction between rabbit erythrocytes and emulsions prepared with various oil concentrations. No hemolysis caused by an interaction between rabbit erythrocytes and vesicles prepared with PEL at a concentration of 0.012% was observed. However, hemolysis levels of 64.2% and 91.1% were observed at PEL concentrations of 0.12% and 1.2%, respectively. These results led to the conclusion that hemolysis caused by the interaction between erythrocytes and emulsions was due to PEL vesicles in the water phase of the emulsions.     

Physicochemical properties of nevirapine-loaded solid lipid nanoparticles and nanostructured lipid carriers

Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) coated with human serum albumin (HSA) were fabricated for formulating nevirapine (NVP). Here, NLCs contained low-melting-point oleic acid (OA) in the internal lipid phase. The results revealed that the two nanoparticles were uniformly distributed with the average diameter ranging from 145 to 180 nm. The surface HSA neutralized the positive charge of dimethyldioctadecyl ammonium bromide (DODAB) on SLNs and NLCs and reduced their zeta potential. In a fixed ratio of solid lipids, SLNs entrapped more NVP than NLCs. The incorporation of OA also reduced the thermal resistance of NLCs and accelerated the release of NVP from the nanocarriers. When incubated with DODAB-stabilized SLNs, the viability of human brain-microvascular endothelial cells (HBMECs) reduced. However, the surface HSA increased the viability of HBMECs about 10% when the concentration of SLNs was higher than 0.8 mg/mL. HSA-grafted SLNs and NLCs can be effective formulations in the delivery of NVP for viral therapy.     

Advances in lipid carriers for drug delivery to the gastrointestinal tract

Lipid-based formulations have re-emerged as oral drug delivery systems. Advances in the techniques to evaluate the in vivo fate of the formulations, together with an improved knowledge of the gastrointestinal processes/barriers to the evolving lipid-based systems, could explain, at least partially, this revival. In addition, the use of lipid-based formulations is no longer limited to highly lipophilic drugs and has been extended to hydrophilic peptides and macromolecules. Last but not least, (targeted) nanocarriers have been developed exploiting gut physiology toward novel targets in the field. We herein review what we believe have been the major advances in oral drug delivery via lipid-based formulations in recent years, leading to their re-emergence as promising drug delivery systems for future clinical application.     

Physicochemical aspects of drug delivery and release from polymer-based colloids

Recent advances in the preparation/loading, surface properties, and applications of polymer-based colloidal drug delivery and release systems, such as block copolymer micelles, polymer nano- and microparticles, polymer-modified liposomes, and chemical and physical hydrogels are presented. Drug release from polymer-based systems is affected by the drug–polymer interactions as well as the polymer microstructure and dissociation/erosion properties. Surface modification with poly(ethylene oxide) has become common in improving the biocompatibility and biodistribution of drug delivery carriers. Site-specific drug delivery can be achieved by polymer-based colloidal drug carriers when ligands of targeting information are attached on the carrier surface or when a phase transition is induced by an external stimulus. While significant progress in being made, many challenges remain in preserving the biological activity and attaining the desired drug release properties, especially for protein and DNA drugs.     

Exosome-based drug delivery systems in cancer therapy

Exosome, which is a kind of extracellular vesicles with size around 40-160 nm, plays an important role in cell-to-cell communication in multiple diseases. Especially in tumor microenvironment, exosomes are the important pathway to transit proteins, nucleic acids and small molecules between different kinds of cells. Based on these characteristics, exosomes are served as both therapeutic agents and drug delivery systems in cancer therapy. In this review, the applications of exosomes as drug delive...     

Erythrocyte-derived drug delivery systems in cancer therapy

As natural blood components,erythrocytes were good candidates for being used as drug delive ry systems to improve the pharmacokinetics,biocompatibility and many other aspects of different drugs.The advantages brought by erythrocytes making erythrocyte-derived drug delivery systems,also known as erythrocyte carriers,suitable for various anti-cancer agents,especially newly invented agents like nanoparticles,which were characterized by their undesired systematic toxicity,anaphylactic reactions and poor biocompatibility.Current researches on erythrocyte carriers in ca ncer therapy showed inspiring results in four major aspects:cancer enzyme therapy,delivering chemotherapeutic agents,combining with nanoparticles,and several other anti-cancer agents for gene or immune therapy.This novel delivering system was now undergoing the translation process from laboratory to clinical practice.Erythrocyte carriers for cancer enzyme therapy have entered the stage of clinical trial and have showed promising outcomes,and others were still at pre-clinical stage.In summary,erythrocyte-derived drug delivery system might play an indispensable role in the management of cancer in the future.     

Structural characterization of novel phospholipid lipid nanoparticles for controlled drug delivery

Drug-phospholipid lipid nanoparticles (DPLNs) are prepared by incorporating drug-phospholipid complexes (DPCs) with a liquid lipid. DPLNs demonstrated interesting properties including increased encapsulation capacity, improved stability and controlled drug release profile. A comprehensive characterization of DPLNs was presented and then a schematic model was suggested according to the characterization results. Transmission electron microscopy and scanning electron microscope measurements showed the morphology of DPLNs. X-ray diffraction exhibited a predominantly amorphous structure for DPCs and totally amorphous for DPLNs. Laser confocal scanning microscopy revealed the relative position of DPCs and liquid lipid, showing that DPLNs formed a homogeneous system. Fluorescence spectra and electron spin resonance further confirmed the chemical environment inside the DPLNs in a non-invasive way.     

Therapeutic systems and controlled drug delivery

Therapeutic systems can provide pre-programmed, unattended delivery of a drug at a rate, and for a time period, established to meet a specific therapeutic need. The system can be designed to minimize the patient's intervention and to optimize compliance with the prescribed regimen. The ocular therapeutic system described here for the control of intraocular pressure in glaucoma delivers pilocarpine at 20 or 40 μg/h for one week, and fits comfortably into the cul-de-sac of the eye. The intrauterine progesterone contraceptive system described here represents a new approach to steroidal contraception that localizes the effect of the hormone progesterone to the uterus, delivering the hormone at a rate of 65 μg/day for one year. Both of these systems are designed to deliver drug into their immediate locale, and are thus topical dosage forms. The transdermal therapeutic system described here has been designed to deliver scopolamine across intact skin and into systemic blood to achieve an antinausea effect. The pharmacokinetics of scopolamine are such that, to minimize the time required for the onset of drug action, drug should be presented at an initially high rate, i.e. as a priming dose, to attain the therapeutically effective drug level, and then at a constant rate, so as to maintain the therapeutically effective level. This system functions according to the priming dose/maintenance rate design requirement.     

Cyclodextrin based novel drug delivery systems

The versatile pharmaceutical material cyclodextrin’s (CDs) are classified into hydrophilic, hydrophobic, and ionic derivatives. By the early 1950s the basic physicochemical characteristics of cyclodextrins had been discovered, since than their use is a practical and economical way to improve the physicochemical and pharmaceutical properties such as solubility, stability, and bioavailability of administered drug molecules. These CDs can serve as multi-functional drug carriers, through the formation of inclusion complex or the form of CD/drug conjugate and, thereby potentially serving as novel drug carriers. This contribution outlines applications and comparative benefits of use of cyclodextrins (CDs) and their derivatives in the design of novel delivery systems like liposomes, microspheres, microcapsules, nanoparticles, cyclodextrin grafted cellulosic fabric, hydrogels, nanosponges, beads, nanogels/nanoassemblies and cyclodextrin-containing polymers. The article also focuses on the ability of CDs to enhance the drug absorption across biological barriers, the ability to control the rate and time profiles of drug release, drug safety, drug stability, and the ability to deliver a drug to targeted site. The article highlight’s on needs, limitations and advantages of CD based delivery systems. CDs, because of their continuing ability to find several novel applications in drug delivery, are expected to solve many problems associated with the delivery of different novel drugs through different delivery routes.     

Synthesis of archaeal bipolar lipid analogues: a way to versatile drug/gene delivery systems

A synthetic route for the preparation of symmetrical and unsymmetrical archaeal tetraether-like analogues has been described. The syntheses are based upon the elaboration of hemimacrocyclic tetraether lipid cores from versatile building blocks followed by simultaneous or sequential introduction of polar head groups. Functionalizations of the tetraether lipids with neutral lactose or phosphatidylcholine polar heads and cationic glycine betaine moieties were envisaged both to increase membrane stability and to exhibit interactions with charged nucleic acids. Additionally, mannose and lactose triantennary clusters designed as multivalent ligands for selective interaction with lectin-type receptors were also efficiently synthesized for active cell/tissue targeting.     

A new biodegradable polydepsipeptide microsphere for application in drug delivery systems

A sequential polydepsipeptide containing a tripeptide sequence L-alanyl-Lalanyl-ethyl L-glutamyl and an-hydroxy acid L-lactic acid, poly(Ala-Ala-Glu(OEt)-Lac), was synthesized to prepare the microspherical particles by the solvent evaporation process. In this case, the solvents play the most important role for the preparation of polydepsipeptide microspheres and, as an example, when 200 mg of the polydepsipeptide dissolved in 10 ml of 98/2% chloroform/dichloroacetic acid mixture was stirred at 400 rpm and 30 C, the microspherical particles with mean diameter of 58m were formed after pouring into 200 ml of 1% (w/v) poly(vinyl alcohol) solution. 17-Estradiol was incorporated into the particles, and the resulting particles were found to contain 5 mg of drug per 25 mg of the particle. The in vivo release of drug from the microspherical formulation was evaluated by measuring the pharmacological influence on rat prostate. It was found that the sufficient amount of drug, keeping the effective pharmacological influence, is supplied during the first 12-week period, followed by an incomplete supplying of drug intil the implant is perfectly degraded in vivo in the 25th week from the start of implantation.     

Theoretical investigation of functionalized fullerene nano carrier drug delivery of fluoxetine

In recent years, fullerene nanoparticles have received extensive attention due to their unique physical and chemical properties. Properly modified fullerene nanoparticles have excellent biocompatibility and significant anti-tumor activity and anti-depression, which makes them have broad application prospects in the field of cancer anti-depression. The present study used the density functional theory (DFT) calculations to perform a theoretical examination of the interaction of fluoxetine (F) as medicine with the functionalized fullerene O and NO (F–O and F–NO surface in gas phase physiological media. According to DFT calculations, adsorption energies were ?3396.6350645, ?3540.2952907, ?6778.526894, and ?6952.251487 kJ for F/P complexes (fullerene O and NO (F–O and F–NO surface) respectively, proposing the possibility of the adsorption process of F molecule onto the fullerene surface concerning the energetic perspective. Calculations of electronic parameters aimed at determining the molecule's reactivity. Bandgap of F–O and F–NO were 0.03715, 0.04328 respectively, by this value we can recognize the reactivity of complexes.